PRL-3 Inhibitor is primarily used in cancer research due to its ability to target and suppress the activity of the PRL-3 phosphatase enzyme, which is overexpressed in various malignancies including colorectal, ovarian, and gastric cancers. By inhibiting PRL-3, this compound helps block signaling pathways involved in tumor cell proliferation, migration, and metastasis. It is being investigated for its potential to reduce cancer progression and improve response to other anticancer therapies. Its application is especially valuable in developing targeted treatments where PRL-3 contributes to aggressive tumor behavior.